Obsidian Therapeutics, Inc. (OBX)
$17.12-$0.03 (-0.17%) Latest session
Latest OBX Insider Trades
Robert W. Ross - DirectorGrant or award37,653 sh
Robert W. Ross - Director
Maria Fardis - DirectorObsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 6 | 225,918 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
6 Form 4 filings on record, the earliest from Aug 5, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Robert W. Ross - Director | Grant or award | Stock Option (Right to Buy) | 37,653 | $0.00 | - | |
| Matthew Norkunas - Director | Grant or award | Stock Option (Right to Buy) | 37,653 | $0.00 | - | |
| Madan Jagasia - Officer | Grant or award | Stock Option (Right to Buy) | 37,653 | $0.00 | - | |
| Peter Barrett - Director | Grant or award | Stock Option (Right to Buy) | 37,653 | $0.00 | - | |
| Heidi Hagen - Director | Grant or award | Stock Option (Right to Buy) | 37,653 | $0.00 | - | |
| Maria Fardis - Director | Grant or award | Stock Option (Right to Buy) | 37,653 | $0.00 | - |
Obsidian Therapeutics, Inc. (OBX) had 6 insider filings in the last 90 days, with the most recent on 2026-08-05. The full record for OBX runs to 6 Form 4 filings, the earliest from 2026-08-05. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of OBX were filed in the last 90 days.
No insider sales of OBX were filed in the last 90 days.
This page tracks OBX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add OBX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
